Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets open weak
Thu, 30 May 09:30 am

Barring South Korea (up 0.1%), the major Asian equity markets have opened the day in the red with Japan (down 3.6%) and Singapore (down 1.4%) leading the losses. The Indian share market indices have also opened the day on a weak note. Barring auto, healthcare and FMCG, all sectoral indices have opened in the red led by stocks in oil and gas and realty space.

The Sensex today is lower by around 38 points (0.2%), while the NSE-Nifty is down by around 15 points (0.3%). Mid and small cap stocks are also trading in the red with the BSE Mid Cap and BSE Small Cap indices down by around 0.1% and 0.2% respectively. The rupee is trading at Rs 56.12 to the US dollar.

Energy stocks have opened on a mixed note with Cairn India Ltd and Oil and Natural Gas Corporation Ltd (ONGC) leading the losses. However, Bharat Petroleum Corporation Ltd (BPCL) and Oil India Ltd (OIL) have opened in the green. Leading oil and gas exploration firm ONGC has announced its results for the fourth quarter ending March 2013 The revenue growth for the quarter came at 13% year on year (YoY). The oil output declined by 2.8% YoY while gas production was down by 7% YoY during the quarter. ONGC had to shell out more towards royalty and cess payments because of which the margins were impacted. The statutory levies increased during the quarter and ONGC had to make higher provision for dry wells and survey expenditure. The net profits for the quarter declined by 40% YoY. The subsidy outgo for the quarter stood at Rs 123 bn, lower than Rs 141.7 bn in 4QFY12. In FY13, the bottomline declined by 16.7% YoY, mainly on account of high subsidy payout.

Indian Pharma stocks have opened on a mixed note with Dishman Pharma and IPCA Labs leading the pack of gainers. However, Wockhardt Ltd and Panacea Biotech Ltd have opened the day in the red. The generic drug maker Cipla Ltd has announced its results for the quarter ending March 2013. The company has reported a 2.4 % year on year (YoY) growth in sales for the quarter. The operating profit margins for the quarter stood at 20.7%. The bottomline during the quarter was down by 8.2% YoY. The company's board has recommended a dividend of Rs 2 per equity share for FY13. For FY13, total revenues were up 17.5% YoY while the bottomline was up by 34% YoY.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets open weak". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.